Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 10/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14370635 | 1.00 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4883469 | 0.92 | MAOA (0.47) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4881245 | 0.90 | MAOA (0.59) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14197134 | 0.90 | MAOA (0.59) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14370616 | 0.89 | MAOA (0.52) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4883517 | 0.89 | MAOA (0.52) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14370641 | 0.88 | MAOB (0.59) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5374073 | 0.88 | MAOB (0.59) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4875613 | 0.88 | MAOB (0.51) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL14370634 | 0.88 | MAOA (0.52) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090884-A1 | ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL- OXAZOLIDINONE DERIVATIVES AND ANALOGUES | PFIZER INC | 2008-04-17 | — | — | US | claimed |
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | claimed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | claimed |
| US-20080090884-A1 | ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL- OXAZOLIDINONE DERIVATIVES AND ANALOGUES | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | OXA1L, CYP51A1, CYP2C19 | MAOA 1957/4885MAOB 1797/4885LMNA 3131/4885 |
| US-20080090884-A1 | ANTIMICROBIAL [3.1.0] BICYCLOHEXYLPHENYL- OXAZOLIDINONE DERIVATIVES AND ANALOGUES | OXA1L, CYP51A1, CYP2C19 | MAOA 1931/4885MAOB 1736/4885LMNA 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.